SWOG clinical trial number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

Open
Phase
III
Abbreviated Title
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Activated
05/01/2021
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Nivolumab Atezolizumab durvalumab Avelumab Pembrolizumab

Eligibility Criteria Expand/Collapse

Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (https://www.ctsu.org) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A031901
SWOG Clinical Trial Number
CTSU/EA8185